Clinical Trial Update: Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating fractionated dosing of darbepoetin alfa to treat anemia in subjects with non-myeloid malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Non-Myeloid Malignancies, Anemia | Phase 2 | Status: COMPLETED